

Servier appoints David K. Lee to Executive Committee

Suresnes (France), January 13th, 2025 - Servier, an independent international pharmaceutical group, announces the appointment of David K. Lee to its Executive Committee as Executive Vice President for the United States, effective January 1, 2025.

David K. Lee has held the position of Chief Executive Officer (CEO) of Servier Pharmaceuticals in the United States since the creation of this subsidiary in 2018. Under his leadership, it has become the Group's leading entity with five oncology drugs. David K. Lee will continue to lead Servier's activities in the United States and will contribute, as a member of the Executive Committee, to the definition and implementation of the Group's global strategy.

David K. Lee holds a degree in biochemistry from Harvard College and an MBA from Harvard Business School. A recognized leader in the pharmaceutical industry, he has held senior positions at Baxalta and Novartis. Before joining Servier, David K. Lee was the Global Head of the Rare Diseases and Oncology franchises at Shire, where he oversaw cross-functional leadership teams responsible for strategy, marketing, business development, R&D, and support functions. He played a key role in Servier's acquisition of Shire's oncology portfolio and later the oncology division of Agios.

Press contact
presse@servier.com

About Servier

Founded to serve health, Servier is an independent international pharmaceutical group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,900 employees of the Group are committed to this shared vocation, source of inspiration every day.

As a world leader in cardiology, Servier's ambition is to become a focused and innovative player in oncology by targeting hard-to-treat cancers. That is why the Group allocates over 70% of its R&D budget to developing targeted and innovative therapies in oncology.

Neuroscience and immuno-inflammatory diseases are the future growth drivers. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine.

To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, relying on strong brands in France, Eastern Europe and in Brazil.

In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine.

Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries and achieved a revenue of €5.3 billion in 2023.

More information on the new Group website: servier.com
Follow us on social media: [LinkedIn](#), [Facebook](#), [Twitter](#), [Instagram](#)